Eplontersen is granted FDA Fast Track Designation for Amyloid Cardiomyopathy Mediated by Transthyretin.

Published Date: 29 Feb 2024

A phase 3 study called CARDIO-TTRansform, which will have data read out in 2025, will continue to evaluate antisense oligonucleotide.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

2.

New drug combination shows good results in patients with HPV-negative head and neck cancer

3.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

4.

Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC

5.

Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot